低分子肝素在弥散性血管内凝血患者的应用研究

Application of low molecular weight heparin in patients with disseminated intravascular coagulation

目的研究低分子肝素应用于治疗弥散性血管内凝血(DIC)的临床疗效和安全性。方法将87例DIC患者按照治疗药物不同分为低分子肝素组和普通肝素组。观察监测凝血功能、疗效、28 d病死率以及不良反应。结果研究组治愈率以及有效率较对照组高,但差异无统计学意义,各症状的疗效也相当,但其对于部分凝血活酶(APTT)延长的影响更小,治疗后研究组APTT延长的患者数明显减少,而对照组治疗后APTT延长的患者数有所增高,研究组28 d死亡率与对照组相似,但出血例数更少。结论低分子肝素疗效与普通肝素相似,但出血等不良反应更少,更为安全有效。

Objective To study the clinical efficacy and safety of low molecular weight heparin in the treatment of disseminated intravascular coagulation（DIC）.Methods Eighty-seven DIC patients were divided into low molecular weight heparin group and unfractionated heparin group in accordance with different therapies.Coagulant function,efficacy,28d mortality rate,and adverse reactions were observed.Results The cure rate and efficiency in the study group were higher than those in the control group,but the differences were not statistically significant.The efficacies of the various symptoms were almost the same,but they had smaller impact on prolonging activated partial thromboplastin time（APTT）.After treatment,the number of patients with prolonged APTT in the study group was significantly reduced.While the number of patients with prolonged APTT in the control group were significantly increased.The study group had similar mortality rate at day 28 with the control group but there were fewer hemorrhagic patients.Conclusion The efficacy of low molecular weight heparin with unfractionated heparin is similar,but the adverse reactions such as bleeding are fewer.Thus it is safer and more effective.